- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/28 - Radicals substituted by singly-bound oxygen or sulfur atoms
Patent holdings for IPC class C07D 213/28
Total number of patents in this class: 23
10-year publication summary
|
1
|
2
|
0
|
2
|
0
|
0
|
3
|
0
|
1
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| sanofi-aventis | 365 |
4 |
| Centre National de La Recherche Scientifique | 10442 |
2 |
| Abbvie Inc. | 1800 |
2 |
| Battelle Memorial Institute | 2491 |
2 |
| Novartis AG | 10829 |
1 |
| Dow AgroSciences LLC | 1223 |
1 |
| Givaudan SA | 1889 |
1 |
| GW Research Limited | 193 |
1 |
| Icahn School of Medicine at Mount Sinai | 952 |
1 |
| Medical Research Council | 154 |
1 |
| Universite Rene Descartes (Paris V) | 14 |
1 |
| IFM Therapeutics, Inc | 1 |
1 |
| Vivace Therapeutics, Inc. | 30 |
1 |
| Sanofi | 4068 |
1 |
| Xyzagen, Inc. | 16 |
1 |
| Pharma IP Limited Liability Intermediary Corporations | 2 |
1 |
| Université Paris Cité | 793 |
1 |
| Other owners | 0 |